Vanguard Group Inc Axcella Health Inc. Transaction History

Vanguard Group Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.31 - $0.77 $16,702 - $41,486	53,878 Added 7.0%	823,429 $395,000
Q4 2022 Feb 10, 2023	BUY	$0.16 - $1.1 $70 - $485	441 Added 0.06%	769,551 $253,000
Q3 2022 Nov 14, 2022	BUY	$1.62 - $2.73 $3,078 - $5,187	1,900 Added 0.25%	769,110 $1.32 Million
Q2 2022 Aug 12, 2022	BUY	$1.41 - $2.77 $14,136 - $27,772	10,026 Added 1.32%	767,210 $1.56 Million
Q1 2022 May 13, 2022	SELL	$1.58 - $2.82 $241,392 - $430,839	-152,780 Reduced 16.79%	757,184 $1.95 Million
Q4 2021 Feb 14, 2022	SELL	$2.06 - $3.61 $1,946 - $3,411	-945 Reduced 0.1%	909,964 $1.9 Million
Q3 2021 Nov 12, 2021	BUY	$2.98 - $4.31 $4,529 - $6,551	1,520 Added 0.17%	910,909 $2.72 Million
Q2 2021 Aug 13, 2021	BUY	$3.08 - $5.13 $2.8 Million - $4.67 Million	909,389 New	909,389 $3.65 Million

61.6K

Ticker AXLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,500,896
Description
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrenc...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.